Cspc Mingfule Pharmaceutical (guangzhou) Co., Ltd.

This large Phase 3 trial is testing whether a new clot-dissolving drug (rhTNK-tPA) can help people recover better from a major stroke, even if treatment starts up to 24 hours after symptoms begin. It will enroll about 890 adults who have a blocked brain artery and specific brain …